



US010004726B2

(12) **United States Patent**
Bevill et al.(10) **Patent No.:** **US 10,004,726 B2**(45) **Date of Patent:** ***Jun. 26, 2018**(54) **POLYMORPHS OF COCRYSTALS OF P-COUMARIC ACID:NICOTINAMIDE**(71) Applicant: **AMRI SSCI, LLC**, West Lafayette, IN (US)(72) Inventors: **Melanie Janelle Bevill**, West Lafayette, IN (US); **Nate Schultheiss**, Kingwood, TX (US)(73) Assignee: **AMRI SSCI, LLC**, West Lafayette, IN (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/072,530**(22) Filed: **Mar. 17, 2016**(65) **Prior Publication Data**

US 2016/0279115 A1 Sep. 29, 2016

Related U.S. Application Data

(62) Division of application No. 14/607,186, filed on Jan. 28, 2015, now Pat. No. 9,314,459.

(60) Provisional application No. 61/935,570, filed on Feb. 4, 2014.

(51) **Int. Cl.****A61K 31/455** (2006.01)**A61K 31/192** (2006.01)**A61K 31/00** (2006.01)**C07D 213/82** (2006.01)(52) **U.S. Cl.**CPC **A61K 31/455** (2013.01); **A61K 31/00** (2013.01); **A61K 31/192** (2013.01); **C07D 213/82** (2013.01)(58) **Field of Classification Search**CPC **A61K 31/455**
See application file for complete search history.(56) **References Cited****U.S. PATENT DOCUMENTS**

7,452,555 B2	11/2008	Childs	
8,212,079 B2	7/2012	Childs	
8,350,085 B2	1/2013	Childs	
9,120,766 B2	9/2015	Bevill et al.	
9,314,459 B2 *	4/2016	Bevill	A61K 31/192
2011/0251426 A1	10/2011	Childs et al.	
2013/0102781 A1 *	4/2013	Bevill	C07C 51/43 544/323
2014/0073674 A1	3/2014	Bevill et al.	
2014/0235595 A1	8/2014	Albert et al.	

OTHER PUBLICATIONS

Sekhon, *Ars Pharm*, 2009, vol. 50 n^o 3; 99-117.*
 Breuil, A.C. et al., "Characterization of a pterostilbene Dehydrodimer Produced by Laccase of *Botrytis cinerea*," *Phytopathology* vol. 89, No. 4, pp. 298-302 (1999).

Etter, Margaret C. et al., "Graph-Set Analysis of Hydrogen-Bond Patterns in Organic Crystals," *Acta Cryst.*, B46, pp. 256-262 (1990).
 Etter, Margaret C. et al., "The Use of CocrySTALLIZATION as a Method of studying Hydrogen Bond Preferences of 2-Aminopyridine," *Journal of the Chemical Society, Chemical Communications*, No. 8, pp. 589-591 (1990).

Flack, HD., "On Enantiomorph-Polarity Estimation," *Acta Cryst.*, A39, pp. 876-881 (1983).

Gorbitz, C.H. et al., "On the inclusion of solvent molecules in the crystal structures of organic compounds," *Acta Cryst.*, B56, pp. 526-534(2000).

Hoof, R.W.W. et al., "Determination of absolute structure using Bayesian statistics on Bijvoet differences", *J. Appl. Cryst.*, vol. 41, pp. 96-103 (2008).

Kumar et al., "Molecular Complexes of Some Mono- and Dicarboxylic Acids with trans-1,4-Dithiane-1,4-dioxide," *American Chemical Society, Crystal Growth & Design*, vol. 2, No. 4, pp. 313-318 (2002).

Pezet, R., "Purification and characterization of a 32-kDa laccase-like stilbene oxidase produced by *Botrytis cinerea* Pers.:Fr," *FEMS Microbiology Letters*, vol. 167, pp. 203-208 (1998).

Schultheiss, N. et al., "Nutraceutical cocrySTALS: utilizing pterostilbene as a cocrySTAL former," *Crystal Engineering communications*, vol. 12, pp. 2436-2442 (2010).

Schultheiss, N. et al., "Attempted construction of minoxidil: carboxylic acid cocrySTALS; 7 salts and 1 cocrySTAL resulted," *Crystal Engineering Communications*, vol. 12, pp. 742-749 (2010).

Schultheiss, N. et al., "Attempted construction of minoxidil: carboxylic acid cocrySTALS; 8 salts and 1 cocrySTAL resulted," *Crystal Engineering Communications, Supplementary Material*, pp. 1-19 (2010).

Schultheiss, N. et al., "Nifedipine—pyrazine (2/1)," *Acta Cryst.* E66, pp. 02297-02298 and Sup-I to Sup-9 (2010).

David C. Lee and Michael L. Webb, *Pharmaceutical Analysis*, 2003, pp. 254-259, 1 st edition, CRC Press, Boca Raton, Florida, United States of America.

Nate Schultheiss, et al., "CocrySTALS of nutraceutical p-coumaric acid with caffeine and theophylline: polymorphism and solid-state stability explored in detail using their crystal graphs," *CrystEngComm*, vol. 13, pp. 611-619 (2011) The Royal Society of Chemistry, London, United Kingdom.

Ivanisevic et al., "Uses of X-Ray Powder Diffraction in the Pharmaceutical Industry," *Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing*, pp. 1-42 (2010).

Ivanisevic et al., "Uses of X-Ray Powder Diffraction in the Pharmaceutical Industry," *Pharm. Form Qual.* pp. 30-33 (2011).

Bhattacharya et al., "Thermoanalytical and Crystallographic Methods" in Brittain H. ed. 2nd ed. Informa Healthcare:NY. pp. 318-335(2009).

Aakeroy, "Crystal Engineering: Strategies and Architectures," *Acta Cryst.* B53, pp. 569-586 (1997).

Sekhon BS, "Pharmaceutical co-crySTALS—a review," *Ars Pharm.* 50(3): 99-117 (2009).

(Continued)

Primary Examiner — Nizal S Chandrakumar(74) *Attorney, Agent, or Firm* — LeClairRyan PLLC(57) **ABSTRACT**

Polymorphs, Forms II and III, of cocrySTALS of p-coumaric acid and nicotinamide in a 1:1 molar ratio. Pharmaceutical compositions containing Forms II or III, processes for making such forms, and methods of treatment with such Forms.

12 Claims, 6 Drawing Sheets